Human immunodeficiency virus (HIV) infection has been associated with an increased risk of lymphomas. These lymphomas are preferentially high grade Bnon-Hodgkin lymphomas (NHL), and Hodgkin's lymphomas (HL) [1] . In the combined antiretroviral therapy (cART) era, although the incidence of NHL has declined [2] , HL incidence has remained stable [3] . Age-adjusted incidence of HL in people with HIV/AIDS (PWHA) has been estimated to be 19-fold higher than in the general population [4] . This risk is closely related to CD4 count, being the highest between 50 and 350 CD4 cells/µL [5, 6] . HL risk may also be higher during the first year after starting cART [6, 7] . HL represents the second to third most common non-AIDS defining cancer [3, 8, 9] . Moreover, the number of HL cases is expected to increase during the next years driven by growth and aging of the PWHA population [8] .
In comparison to their HIV-negative counterpart, HIVassociated HL present with frequent high-risk characteristics: 1) often mixed cellularity (MC) histological subtype and Epstein-Barr virus (EBV) infection of the tumor cells [1, 10] , 2) frequent advanced stage [11] and higher International Prognostic Score (IPS) [12, 13] . Until recently, HIV-HL survival had been described to be substantially lower than their HIVnegative counterpart with 5-year overall survival (OS) of 61% among PWHA diagnosed between 1996 and 2010 vs 88% among HIV-negative patients [14] . In the most recent cART era, a retrospective British study [12] and a prospective trial in Germany [15] have shown an improvement of the outcomes of HIV-HL reaching those of HIV-negative patients. However, a population based registry study has recently reported a higher mortality in HIV-infected patients than in non-HIV-infected patients [16] . In the present study, we analyzed the characteristics and outcomes of HIV-related HL in the French ANRS Lymphovir cohort, which includes patients diagnosed in the most recent cART era. We compared their characteristics and outcomes to those of a cohort of HIV-negative patients diagnosed during the same period.
METHODS

Patients
The prospective French Cohort of HIV-related lymphomasFrench National Agency for Research on AIDS and Viral Hepatitis ANRS-CO16 Lymphovir cohort-enrolled consecutive HIV-infected patients with newly diagnosed lymphoma, NHL or HL, in 22 centers between 2008 and 2014. In this report we focus on HL. Data collection included medical history, clinical, biological, and histological presentation, treatment and evolution of HL and HIV infection. The diagnosis was established on the basis of histological analysis according to the World Health Organization (WHO) 2008 classification [1] . A centralized review by expert hematopathologists (coordinated by M. R. and S. P.) of pathological materials was performed to determine the expression of EBV-latent membrane protein-1 (EBV-LMP1) and EBV-encoded RNA 1 (EBER-1) by immunohistochemistry (IHC) and in situ hybridization (ISH), respectively. Lymphoma staging was determined using the Ann Arbor system. Staging evaluation included physical examination, routine laboratory, bone marrow biopsy when clinically relevant, computerized tomography (CT) and PET-scan when available. Each patient was monitored every 6 months with a planned follow-up of 5 years. The choice for lymphoma treatment and/or antiretroviral therapy was left to the discretion of each local practitioner. Revised 2007 Cheson criteria were applied to define complete response (CR), partial response (PR), progressive disease (PD), and relapse [17] . Investigations were performed after approval of the ethics committee (Comité de Protection des Personnes Ile-de-France VII) and national competent authority, and written informed consent was obtained from each patient. The study was registered in ClinicalTrials. gov (NCT01164436). HIV-HL patients were compared with the series of non-HIV-infected patients consecutively diagnosed with HL at Saint-Louis hospital (PB) during the 2000-2013 period and within the same age range (18 to 70 years old).
Statistical Analysis
Continuous variables were summarized as median and interquartile range (IQR), and categorical variables as frequency and percentage. Follow-up was defined from HL diagnosis to the last follow-up. OS was measured from lymphoma diagnosis to last follow-up or to death from any cause. Progression free survival (PFS) was measured from lymphoma diagnosis to progression, relapse or death. The probability of PFS and OS was estimated using the Kaplan-Meier estimate, and differences were compared with the log-rank test. Cox proportional hazards regression models were used to identify predictors of PFS. Covariables considered in this prognostic analysis were histological subtype, CD4 count, and IPS, and its 7 components (age, gender, stage, albumin, hemoglobin, leukocyte, and lymphocyte counts). Covariates with P < .10 in univariable analysis were included in the multivariable model.
In the comparative analysis of outcome between HIVpositive and HIV-negative patients, the 7 components of IPS plus histological subtype were considered. We selected, among the different ways of modeling continuous variables (as continuous variable, after log transformation, as categorical variables defined by tertiles), the one with the lowest Akaike information criterion in Cox models of the PFS. Then, the variables linked either to PFS (using Cox model) or to HIV status (using logistic regression) were selected. Missing values were imputed with SAS 9.3 MI procedure. The variables with a P-value below .10 in at least 1 of the 2 models were retained. The propensity score for each subject, defined as the conditional probability of being HIV-infected given his/her individual covariates, was estimated from a logistic regression including the variables selected at the previous stages. Statistical tests were 2-tailed; P < .05 was considered statistically significant. All statistical computations were performed using SAS software version 9.3 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Demographic and HIV Characteristics
Among the 159 consecutive patients, with newly diagnosed HIV-associated lymphoma, enrolled in the cohort, 69 (43%) were diagnosed with HL. One patient had a stage I nodular lymphocyte predominant HL and has been excluded from the following analyses focusing on classical HL (cHL). The characteristics of the cHL patients are presented in Table 1 . Median age was 44 years, and 87% of the study population was men. HIV infection had been diagnosed for a median of 13 years. Patients had a median CD4 T-cell count at diagnosis of lymphoma of 387 /µL (range 37-1742). At diagnosis of lymphoma, all but one patient had previously received cART, and 65/68 were still under cART. They were receiving either a combination of 2 nucleoside reverse transcriptase inhibitors with a protease inhibitor (n = 27) or with a non-nucleoside reverse transcriptase inhibitor (n = 15), or with an integrase inhibitor (n = 3), 3 nucleoside reverse transcriptase inhibitors (n = 2), and 18 other combinations. Among these 65 patients, 54 (83%) had a plasma HIV-1 RNA viral load below 50 copies /mL. During treatment of cHL and after, all the patients received cART except 1 patient who had a transient interruption of ART during chemotherapy. Of note, 4 patients were diagnosed with cHL within the first 6 months of cART.
Lymphoma Characteristics and Treatment
Histological distribution was 42 MC and 12 scleronodular cHL. Fourteen cases could not be classified because the diagnosis was done on bone marrow, liver, or small needle biopsies. Thirtynine out of 42 (93%) tested cases for in situ EBV were positive. Thirty-six percent of patients had altered performance status (2-4), and 76% had advanced clinical stages (III or IV). Of note, 15 of the 68 patients did not have a bone marrow biopsy, which may have resulted in understaging. Most frequent extranodal involvements were bone or bone marrow (n = 26), liver (n = 17), and/or lung (n = 2). The patients with clinical stage I or II received first-line ABVD (3 to 4 cycles) followed by radiotherapy. All but 1 were in CR at the end of treatment (a 56 yearold male patient had a PR after 4 ABVD and was switched to salvage therapy with ICE followed by autologous bone marrow transplantation leading to a complete response with 1 year follow-up). All but 3 patients with stage III/IV cHL received firstline ABVD/ABVD like regimen. Two patients received first-line BEACOPP. The most frequent toxic events were neuropathy (n = 7, leading to diminishing or interruption of Vinblastin), sepsis (n = 7), pulmonary toxicity (n = 4, leading to withdrawal of Bleomycin in all cases) and cardiac failure (1).
Outcome
Overall, median follow-up since diagnosis of HL was 38 months (IQR: 31 months). Seven progressions and/or deaths were recorded. Two patients relapsed and are in PR: A 46 year-old female patient relapsed 1 year after stage II HL, treated with 4 cycles of ABVD and radiotherapy. She was treated with DHAP/ DHOX and is in PR. A 40 year-old male patient diagnosed with stage III HL relapsed 8 months after initial diagnosis. He was treated with salvage therapy and Brentuximab vedotin and is in PR. Three patients died during the early phase of treatment: A 63 year-old man with infectious comorbidities was diagnosed with stage IV cHL and died less than 2 weeks following diagnosis. A 49 year-old male patient with 50 CD4 cells/µL received etoposide before ABVD because of severe HL-associated hemophagocytic Figure 1 ). The analysis of prognostic factors was limited by the low number of events (n = 7); therefore, we only analyzed factors associated with PFS ( Table 2 ). The only factor associated with the risk of progression or death was age, with an OR of 8.1 [1.0-67.0] for patients aged 45 years or more compared to younger patients. Stage, IPS, and CD4 count were not associated with PFS. As only 1 variable had a P-value <.1, no multivariable analysis was done.
Comparaison With HIV-negative HL
We compared the characteristics and outcomes of patients with HIV-related cHL with a series of 336 HIV-negative patients prospectively recruited in St Louis hospital during the same time period. They were treated with ABVD (80%) or BEACOPP (20%). The initial characteristics strongly differed between the 2 groups of patients ( 
DISCUSSION
We analyzed the characteristics and outcome of HIV-associated cHL diagnosed in the modern cART era. cHL represented more than 40% of lymphomas diagnosed in the French Lymphovir cohort. Most cases corresponded to MC subtype and were EBV associated. They displayed frequent advanced clinical stage and high IPS contrasting with a very good prognosis. Age above 45 years was the only factor associated with poor outcome. Finally, although patients with HIV infection presented with higher risk features, the 2-year PFS of HIV-infected patients with cHL (89%) did not differ from HIV-negative patients diagnosed with cHL during the same time period. The greatest strength of the study is that it is an observational national cohort enrolling patients in the modern cART era. To our knowledge, it is the first study analyzing the characteristics and outcomes of a prospective observational cohort of patients with HIV-related cHL in the modern cART era. A limitation of the cohort is that some French clinical centers did not participate in the cohort. We estimated that half of the patients diagnosed with HIV-related lymphoma registered in the French Hospital Database on HIV (FHDH) have been included in the cohort between 2010 and 2012 (data not shown). However, the clinical characteristics of the patients enrolled in the cohort seem similar to those recently reported by others [12, [15] [16] [17] [18] : More than 75% of patients have advanced stage and 36%, a poor performance status. This does not support a selection bias to the detriment of patients with worse prognosis, which could have distorted the results reported here. The proportion of cHL (43%) among HIV-related lymphomas observed in the cohort is higher than reported in previous time periods (15% in 1996-2000 to 20% in 2006-2010) [14] . It is consistent with the most recent report from a German cohort where cHL has been found to account for 50% of HIV-associated lymphomas in patients with both HIV RNA below 50 copies/mL for more than 12 months and a CD4 cell count of more than 200 cells/µL [18] . The high proportion of cHL reflects the observed temporal trends of HIV-related lymphomas: steady incidence of HIV-related HL contrasting with a declining incidence of HIV-related NHL [8, 14, 19, 20] . Because the risk of NHL decreases with increasing CD4 counts and as the control of immune deficiency due to HIV infection continues to improve, the proportion of cHL cases will likely increase in the population with HIV infection. cHL in HIV infection still displays particular pathological features in the modern cART era. Emphasizing the peculiarity of HIV-related lymphomagenesis and consistently with literature [10, 21] , we observed a predominance of MC subtype and frequent EBV in situ detection. cHL lymphomagenesis in the context of HIV infection has been shown to be linked not only to immune deficiency but also to other mechanisms such as chronic antigen stimulation and B-cell activation [22, 23] . Further studies are needed to dissect the physiopathology of this disease in the context of the modern cART era.
We report here 2-year OS and PFS of 94% [89%; 100%] and 89% [82%, 97%], respectively, in patients with HIV-associated cHL. We confirm, in the setting of an observational cohort prospective study, the striking improvement of the prognosis of these lymphomas in the modern cART era-when compared with the median survival of 8-20 months reported in the precART era [14, 24, 25] . These results are in line with those of Montoto retrospective study [12] and of Hentrich clinical trial [15] reporting 5-year OS of 85% and 2-year OS of 91%, respectively. However, they differ from the recently published American registry study [16] showing a 2-fold increased risk of death in HIV-infected patients with cHL when compared with the general population. Of note, these data were from a less recent period (2000 to 2010), which may have resulted in some more HIV-related mortality. Disparities between outcomes of HIVinfected patients in Europe and in the United States have already been reported and discussed elsewhere [26] . The optimal management of HIV infection in the Lymphovir cohort, as shown by the proportion of 82% of patients with a viral load below 50 copies/µL at cHL diagnosis, certainly contributes to explain the very good outcome we observed. These outcomes patients are indeed similar to those reported in the literature in HIV-negative patients with cHL [27] . When comparing the prognosis of HIV-infected patients with a prospective series of HIV-negative patients recruited in France during the same period of time, we did not see any difference in their outcome. However, the characteristics of the patients were strikingly different, patients with HIV infection, being older, more frequently men, and having more frequent advanced stage and more advanced IPS. Of note, bulky disease, which has been found to be an important prognostic factor in HL stage IIB [28, 29] could not be compared between the 2 groups because these data were not available among HIVinfected patients. We cannot exclude that the proportion of patients with bulky mediastinal disease differed in the 2 groups of patients. To improve the comparability between HIV-positive and HIV-HL cases, we have repeated the analysis among patients with MC subtype only. In the subgroups of 68 HIVnegative and 42 HIV-infected patients with MC subtype, the propensity scores did overlap but HIV status, once again, was not associated with PFS (P = .14, data not shown). Among HIV-infected patients only, the power of the analysis of prognostic factors associated with PFS was limited by the low number of events (n = 7). Age was the only classical adverse risk factors for cHL found associated with PFS. In a recent large (n = 229) multi-institutional retrospective study in which Lymphovir cohort contributed [30] , the CD4 count was the only variable associated with PFS (Hazard-Ratio of 2.55 [1.38-4.70] below 200 cells/µL). However, in this retrospective study, the median CD4 count (180 cells/µL) and the proportion of patients with high CD4 counts (47%) were much lower than in our cohort. These differences in the studied populations probably explain the discrepancies between the results.
In the present study, most patients were treated with the combination of cART and ABVD, which have been found to offer very good outcomes with limited toxicity [12, 31] . In the context of HIV infection, BEACOPP has been shown to be efficient but followed by substantial treatment related morbid/mortality [10, 15] . Therefore, our data are in line with the recently published recommendations concluding that ABVD should be the treatment of choice in patients with HIV-HL [10, 32] . It is remarkable that all 5 patients who died in our study were aged 45 or more, and age was the only unfavorable prognostic feature associated with progression or death. Thus, specific and less toxic therapeutic approaches are needed in these patients, especially because an aging of the HIV-infected population is expected in the next years [8] . Altogether, the most striking observations drawn from the present study are the high frequency of cHL among lymphomas in HIV-infected patients and the persistence of high-risk features, namely, EBV association, MC subtype, and advanced clinical stage contrasting with the remarkable improvement of their prognosis in the modern cART era. The outcomes of HL in HIV-infected patients in the recent cART era do not differ from those of non-HIVinfected patients.
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